graph EGM comparisons
atezolizumab plus bevacizumab plus carboplatin plus paclitaxeltitlebevacizumab plus carboplatin and paclitaxeltitleIMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018 NCT02366143 non squamous - mNSCLC - L1 - all population 400/400IMpower-150 (ABCP vs BPC WT), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 356/336IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018 NCT02366143 non squamous - mNSCLC - L1 - Wild Type (WT) 155/129

Pathology:  non squamous - mNSCLC - L1 - all population;   non squamous - mNSCLC - L1 - Wild Type (WT); 

non squamous - mNSCLC - L1 - all populationnon squamous - mNSCLC - L1 - Wild Type (WT)
IMpower-150 (ABPC vs BPC ; all population) EXPLORATORY, 2018IMpower-150 (ABCP vs BPC WT), 2018IMpower-150 (ABCP vs BPC ; WT-Teff high), 2018
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel3T1T1T1
bevacizumab plus carboplatin and paclitaxel0T0T0T0